# XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies.

Source: https://onco.cc/trials/nct06792435/  
OnCo record `nct06792435` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of XNW27011 in ovarian cancer and colorectal cancer, run by Astellas Pharma Global Development, Inc., active and no longer recruiting.

## Summary

XNW27011 Study of Advanced Solid Tumor Subjects Who Failed Standard Therapies. is a phase 1/2 interventional study registered as NCT06792435 by Astellas Pharma Global Development, Inc., with 240 participants planned, started 2023-07-27 and due to reach its primary completion in 2026-12-30. Interventions recorded: XNW27011, XNW27011. Conditions listed: Pancreatic Adenocarcinoma Metastatic, Lung Cancer (NSCLC), Ovarian Cancer, Colorectal Cancer Metastatic. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT06792435
- Phase: 1/2
- Setting: A Phase I/Ⅱ, First-in-Human Study of XNW27011 in Patients With Locally Advanced and/or Metastatic Solid Tumors
- Sponsor: Astellas Pharma Global Development, Inc.
- Enrolled: 240

## Sources

- ClinicalTrials.gov NCT06792435: https://clinicaltrials.gov/study/NCT06792435

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- drugs: [XNW27011](https://onco.cc/drugs/xnw27011/)
- companies: [Astellas](https://onco.cc/companies/astellas/)

---
JSON: https://onco.cc/api/v1/entities/nct06792435.json